Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Qiagen (QGEN)
:QGEN
Holding QGEN?
Track your performance easily
Earnings Data
Report Date
Feb 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.6Last Year’s EPS
0.55Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 29, 2018
|% Change Since: 4.63%
|Next Earnings Date:Jul 31, 2018
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong sales, earnings, and profitability improvements, despite cautious instrument spending and challenges in China. The company is on track with strategic growth initiatives and has increased its earnings outlook.Company Guidance
During QIAGEN's Q3 2024 earnings call, the company reported exceeding its sales and adjusted earnings outlook, with $502 million in sales representing 6% growth at constant exchange rates (CER). The Diagnostic Solutions product group saw a 10% growth at CER, while consumables and related revenues grew 8% CER, contributing 89% to total sales. Adjusted diluted earnings per share (EPS) were $0.57, surpassing the outlook by $0.03. The company highlighted key product launches, including a 40% CER sales growth for QIAstat driven by increased global demand and FDA clearances. Adjusted operating income margin improved to 29.6%, and free cash flow increased by 73% to $364 million for the first nine months of 2024. QIAGEN reaffirmed its full-year sales outlook of at least $1.985 billion at CER and raised its adjusted EPS target to at least $2.19.Exceeding Sales and Earnings Targets
QIAGEN exceeded its sales outlook with $502 million in Q3, representing 6% growth at constant exchange rates, and adjusted diluted EPS of $0.57, $0.03 above outlook.
Strong Performance in Diagnostic Solutions
Diagnostic Solutions product group saw 10% CER growth, driven by QuantiFERON TB test sales exceeding $100 million for six consecutive quarters.
QIAstat's Significant Growth
QIAstat posted 40% CER sales growth with more than 150 instrument placements, and received FDA clearances for multiple panels.
Improvement in Profitability and Cash Flow
Adjusted operating income margin increased by 3% to 29.6% of sales, with a 73% increase in free cash flow to $364 million for the first 9 months of 2024.
Upgraded Full-Year Earnings Outlook
Adjusted EPS target for 2024 increased to at least $2.19 at CER, up from $2.16.
---
QGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
QGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $43.87 | $44.15 | +0.64% |
| Jul 31, 2024 | $44.49 | $45.80 | +2.94% |
| Apr 29, 2024 | $42.30 | $42.33 | +0.07% |
| Feb 06, 2024 | $44.80 | $43.52 | -2.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Qiagen (QGEN) report earnings?
Qiagen (QGEN) is schdueled to report earning on Feb 05, 2025, TBA Not Confirmed.
What is Qiagen (QGEN) earnings time?
Qiagen (QGEN) earnings time is at Feb 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is QGEN EPS forecast?
QGEN EPS forecast for the fiscal quarter 2024 (Q4) is 0.6.
---